Jazz Pharmaceuticals plc

NASDAQ:JAZZ   3:59:50 PM EDT
123.59
+2.08 (+1.71%)
Positive Earnings Pre-Announcement

Jazz Pharmaceuticals Posts Quarterly Revenue Of $838.1 Million

Published: 11/09/2021 23:10 GMT
Jazz Pharmaceuticals plc (JAZZ) - Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results and Raises Full Year Earnings Guidance.
Q3 Diluted Loss per Share 0.86 USD Versus 2.64 USD Profit Year Ago.
Qtrly Total Revenues Increased 39% to $838.1 Million Compared to 3q20.
Qtrly Adjusted EPS $4.20.
Sees 2021 Revenue $3,020 Million - $3,100 Million.
Sees 2021 Loss per Share $7.00 - $5.40.
Sees 2021 Adjusted Earnings per Share $15.10 - $15.80.
Q3 Earnings per Share View $3.32, Revenue View $832.5 Million -- Refinitiv Ibes Data (analyst estimates).
FY2021 Earnings per Share View $14.52, Revenue View $3.09 Billion -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $866.2 Million
Adjusted EPS is expected to be $3.62

Next Quarter Revenue Guidance is expected to be $862.57 Million
Next Quarter EPS Guidance is expected to be $3.85

More details on our Analysts Page.